Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC includes a print copy delivered by postal mail and on-line access to electronic PDF copies of your subscribed issues.

The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment

Author(s):  Meissner Svenja, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren

Issue:  Mar/Apr 2020 - Volume 24, Number 2
View All Articles in Issue

Page(s):  140-147

Download in electronic PDF format for $65

Abstract:  In New Zealand, there are no liquid formulations of omeprazole commercially available, therefore suspensions must be extemporaneously compounded from solid dosage forms for patients with swallowing difficulties. The funding for solid dosage forms of omeprazole changes frequently, often every one to two years, without consideration of the impact this may have when extemporaneously compounded liquid dosage forms are required. This study examined suspensions compounded from various solid dosage forms of omeprazole with the purpose of identifying suitable quality formulations and evaluating their chemical and physical stability. Six different solid dosage forms of omeprazole that are available in New Zealand, including capsules, tablets, and powder, were used to prepare 2-mg/mL suspensions in 8.4% w/v sodium bicarbonate solution. The suspensions were then assessed visually for quality and by quantifying sedimentation rate over 120 minutes. Two products, stored in amber bottles at either 4°C or 25°C, demonstrated acceptable quality over a 30-day period whilst monitoring physical and chemical stability on day 0, 7, 14, 20, and 30. Four of the formulated suspensions were deemed to be of poor quality due to either a lack of uniformity or rapid sedimentation, attributes that could lead to inaccurate dosing. Acceptable quality suspensions were prepared from Losec and Dr. Reddy’s brands of omeprazole 20-mg capsules. For both brands, a change in color was observed after 20 days and 7 days when stored at 4°C and 25°C, respectively. Chemical stability was determined using a stability-indicating high-performance liquid chromatographic method, with >90% of the active remaining for 30 days when kept at 4°C, and 20 days when stored at 25°C. Not all brands are suitable for extemporaneously compounding omeprazole suspensions. Losec and Dr. Reddy’s brands of capsules were suitable to prepare quality omeprazole suspensions. Omeprazole suspensions compounded from these products are stable for 20 days if stored at 4°C and protected from light.

Related Keywords: Svenja Meissner, BPharm, Mahima Bansal, BPharm, MHSc, Paula Donamae Dela Cruz, BPharm, Sara Hanning, BPharm, PhD, Darren Svirskis, BHB, BPharm, PhD, New Zealand, omeprazole, proton pump inhibitor, gastroesophageal reflux disease, GERD, gastric ulcer, liquid suspensions, solid dosage forms, proprietary formulations, physical stability, chemical stability

Related Categories: GASTROENTEROLOGY, PEER-REVIEWED, STABILITIES, COMPATIBILITIES, DOSAGE FORMS/DRUG CARRIERS, STORAGE

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
The Effect of Manufacturer on the Compounding of Omeprazole Suspensions and Their Stability Assessment
Meissner Svenja
, Bansal Mahima, Dela Cruz Paula Donamae, Hanning Sara, Svirskis Darren
Mar/Apr 2020
Pg. 140-147

Chemical Stability of Extemporaneously Compounded Omeprazole Formulations: A Comparison of Two Methods of Compounding
Garg Sanjay
, Svirskis Darren, Al-Kabban Majid, Farhan Samer, Komeshi Mohammed, Lee Jacky, Liu Quincy, Naidoo Sacha, Kairuz Therese
May/Jun 2009
Pg. 250-253

The Influence of Tablet Formulation, Drug Concentration, and pH Modification on the Stability of Extemporaneously Compounded Levothyroxine Suspensions
Svirskis Darren
, Lin Shao-Wei, Brown Helen, Sangaroomthong Annie, Shin Daniel, Wang Ziqi, Xu Hongtao, Dean Rebecca, Vareed Preetika, Jensen Maree, Wu Zimei
Mar/Apr 2018
Pg. 164-171

Proton Pump Inhibitor Homogenous Suspensions: A Compounding Solution to Pediatric Gastroesophageal Reflux Disease
Corsini Lindsay
, Williams LaVonn A
Mar/Apr 2011
Pg. 124-128

Alcohol-free Extemporaneous Formulations of Furosemide Are Chemically and Physically Stable in Ora-Blend Products for 30 Days
Svirskis Darren
, Jaffer Johaina, Agarwal Priyanka, Khan Ayeshah, Kaur Jaskarn, Cheng Alan, Hanning Sara
May/Jun 2020
Pg. 246-251

Omeprazole 1 mg/mL and 4 mg/mL in Humco Flavor Sweet Sugar-Free Oral Liquid
Allen Loyd V Jr
Jan/Feb 2019
Pg. 58

Formulation and Pharmaceutical Evaluation of Extemporaneous α-arbutin Creams for the Treatment of Melasma
Teeranachaideekul Veerawat
, Boonsongsawat Worrawee, Asanawittaya Waralee, Jintapattanakit Anchalee, Chantasart Doungdaw, Wongrakpanich Amaraporn
Jan/Feb 2021
Pg. 62-72

Investigation of Filler Effects on the Compounding of Freeze-dried Orodispersible Tablets Containing Annona muricata Extract
Azman Syahiera Ezzah Noor
, Abd Razak Fashli Syafiq, Kamal Wan Hamirul Bahrin Wan, Zheng Gan Kok, Ming Long Chiau, Uddin ABM Helal, Sarker Zaidul Islam, Bin Liew Kai
Nov/Dec 2020
Pg. 509-514

Setting Up a National System of Compounding Pharmacies: Preventing Error, Assuring Quality, Building Trust
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Nov/Dec 2009
Pg. 532-536

PostScription: Setting up a National System of Compounding Pharmacies: An Introduction
Guedes de Souza Hugo
, Favaro Alvaro Jr, Andrade Alba Livia, Gomes Lenir Yago, de Souza Aguiar Simone, do Carmo Garcez Maria
Sep/Oct 2009
Pg. 447

Particle Measuring Systems - USP <797> Environmental Monitoring Solutions